What Could Set Eli Lilly Stock on Fire

Eli Lilly (LLY) has demonstrated significant rally potential, with multiple instances of its stock surging over 30% in under two months. Notably, it recorded more than 50% rallies twice, including key upswings in 2021 and 2025. These powerful gains highlight Eli Lilly’s capacity for rapid advances, suggesting that future catalysts could drive the stock to substantial new highs based on its strong historical performance.

Specifically, we see these catalysts:

1. Next-Generation Obesity & Cardiometabolic Pipeline Maturation
2. Alzheimer’s Franchise Advancement with Donanemab
3. Manufacturing Scale-Up Driving Margin Expansion

Catalyst 1: Next-Generation Obesity & Cardiometabolic Pipeline Maturation

• Details: Potential for multi-billion dollar revenue streams from Orforglipron and Retatrutide, Significant market share capture in the projected $100 billion obesity market,
• Segment Affected: Cardiometabolic Health
• Potential Timeline: Throughout 2026
• Evidence: Orforglipron (oral GLP-1) shows significant weight loss and A1C reduction in Phase 3 trials, with potential FDA approval in Q1 2026., Retatrutide (triple-hormone-receptor agonist) demonstrated a mean weight loss of over 28% in Phase 3, with seven more trial readouts expected in 2026.,

Sources: AInvest Reports, Motley Fool Articles, Nasdaq Publications

Catalyst 2: Alzheimer’s Franchise Advancement with Donanemab

• Details: Establishes a new major therapeutic franchise in neuroscience, Potential to capture a significant share of the growing multi-billion dollar Alzheimer’s market.,
• Segment Affected: Neuroscience
• Potential Timeline: Immediate and ongoing through 2026
• Evidence: Donanemab (Kisunla) received full FDA approval in July 2024, showing significant slowing of cognitive and functional decline in Phase 3 trials., Long-term extension studies show sustained benefits and a consistent safety profile over three years, supporting its use.,

Sources: Moomoo, PhillyVoice, Labiotech.eu, European Pharmaceutical Review

Catalyst 3: Manufacturing Scale-Up Driving Margin Expansion

• Details: Increase in gross and operating margins due to economies of scale and improved production efficiency., Enhanced revenue capture by meeting the high demand for key products like Zepbound and Mounjaro,
• Segment Affected: General Corporate/Manufacturing
• Potential Timeline: Mid-2026 and beyond
• Evidence: Over $50 billion committed to U.S. capital expansion for manufacturing since 2020, with four new sites planned., Anticipated 50% increase in sellable doses of key GLP-1 medicines in the second half of the year compared to the previous year.,

Sources: BioPharma Dive, Contract Pharma, AP News, PR Newswire

But The Stock Is Not Without Its Risks

Here are specific risks we see:

• GLP-1 Price War Eviscerates Margins
• Manufacturing Failures Cap Growth
• Revenue Concentration Implosion

Looking at historical drawdown during market crises is another lens to look at risk.

LLY fell 43% in the Dot-Com crash, 51% in the Global Financial Crisis, and around 19-22% in the 2018, Covid, and Inflation shocks. Risk sticks around despite positives.

Reference: Current Fundamentals

• Revenue Growth: 36.8% LTM and 23.4% last 3-year average.
• Cash Generation: Nearly -0.09% free cash flow margin and 43.0% operating margin LTM.
• Valuation: Eli Lilly stock trades at a P/E multiple of 70.0

*LTM: Last Twelve Months | If you want more details, read Buy or Sell LLY Stock.

Still not convinced about LLY stock? Consider Portfolio Approach

A Multi Asset Portfolio Beats Picking Stocks Alone

Individual picks are volatile but diversified assets offset each other. A multi asset portfolio helps you stay the course capture upside and reduce downside.

The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices